Diabetes therapies in renal impairment

Bailey, Clifford J. and Day, Caroline (2012). Diabetes therapies in renal impairment. British Journal of Diabetes and Vascular Disease, 12 (4), pp. 167-171.

Abstract

Depending on age, duration of diabetes and glycaemic control, 20-40% of patients with type 2 diabetes will incur a moderate or severe deterioration of renal function. This will impact the choice of blood glucose-lowering therapy and require more frequent monitoring of both renal function and glycaemic control. Moderate renal impairment (glomerular filtration rate 30-<60 ml/min) requires consideration of dose reduction or treatment cessation for metformin, glucagon-like peptide-1 receptor agonists, some sulphonylureas and some dipeptidyl peptidase-4 inhibitors. At lower rates of glomerular filtration down to about 15 ml/min it may be appropriate to use a meglitinide, pioglitazone or certain sulphonylureas with careful consideration of dose and co-morbidities. Dipeptidyl peptidase-4 inhibitors can be used at reduced dose in patients with very low rates of glomerular filtration, and linagliptin can be used without dose reduction, and has been used in patients on dialysis. Insulin can be used at any stage of renal impairment, but the regimen and the dose must be suitably adjusted and accompanied by adequate monitoring.

Publication DOI: https://doi.org/10.1177/1474651412458811
Divisions: Life & Health Sciences > Biosciences
Uncontrolled Keywords: Albuminuria,type 2 diabetes,renal impairment,kidney disease,drug therapy
Published Date: 2012-07

Download

Full text not available from this repository.

Export / Share Citation


Statistics

Additional statistics for this record